InnovivaINVA
INVA
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
6,479% more call options, than puts
Call options by funds: $921K | Put options by funds: $14K
63% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 59
62% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 21
6% more funds holding
Funds holding: 218 [Q3] → 231 (+13) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
3.08% less ownership
Funds ownership: 116.71% [Q3] → 113.63% (-3.08%) [Q4]
13% less capital invested
Capital invested by funds: $1.41B [Q3] → $1.23B (-$180M) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$55
207%
upside
Avg. target
$55
207%
upside
High target
$55
207%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Scotiabank Louise Chen 35% 1-year accuracy 46 / 133 met price target | 207%upside $55 | Sector Outperform Initiated | 7 Mar 2025 |
Financial journalist opinion
Based on 3 articles about INVA published over the past 30 days
Neutral
24/7 Wall Street
2 weeks ago
Billionaire Healthcare Investor Alex Denner's Hedge Fund Has 75% of Its Assets in These 3 Stocks
If you work in the biotech industry, you might know the name Alex Denner.
Neutral
PRNewsWire
2 weeks ago
Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva
Proceeds to be used to continue to advance development of Armata's phage product candidates LOS ANGELES , March 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a secured credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"), Armata's largest shareholder. The gross proceeds to be received by the Company at closing are $10 million before deducting transaction-related expenses.
Neutral
Business Wire
3 weeks ago
Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Barclays 27th Annual Global Healthcare Conference in Miami, FL on.
Neutral
Business Wire
1 month ago
Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the fourth quarter and full year ended December 31, 2024, and highlighted select corporate progress and achievements. Pavel Raifeld,.
Positive
Seeking Alpha
1 month ago
Innoviva: Underappreciated Strength In Hospital Therapeutics
Innoviva's strong balance sheet and stable royalty income from GlaxoSmithKline provide a solid foundation for its shift to specialty therapeutics, presenting an asymmetric risk-reward profile. The company is transitioning from a royalty collector to an operator in specialty therapeutics, with significant growth in product sales, notably GIAPREZA and XACDURO. Key assets like Zevtera, an advanced-generation antibiotic, and a promising pipeline in infectious diseases, position Innoviva for potential market disruption and growth.
Neutral
Business Wire
1 month ago
Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a podium presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conference.
Neutral
Business Wire
3 months ago
Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., (“IST”) a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced it has entered into an exclusive distribution and license agreement with Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), for the commercialization of Zevtera® (ceftobiprole), an advanced-generation cephalosporin antibiotic, in the United States. "The licensing of Zevtera expands IST's diverse yet complementary portfolio of differentiated treatments.
Neutral
GlobeNewsWire
3 months ago
Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 16, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an exclusive distribution and license agreement with Innoviva Specialty Therapeutics, Inc., a wholly owned subsidiary of Innoviva Inc. (NASDAQ: INVA), for the commercialization of Basilea's hospital anti-MRSA antibiotic Zevtera® (ceftobiprole) in the United States (US).
Neutral
Business Wire
4 months ago
Innoviva to Participate in the Citi 2024 Global Healthcare Conference
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Citi 2024 Global Healthcare Conference in Miami, FL on Thursday,.
Neutral
Business Wire
4 months ago
Innoviva to Participate in the UBS Global Healthcare Conference
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in a fireside chat at the UBS Global Healthcare Conference in Ranch Palos Verdes, CA on Wednesday, November 13, 2024 at.
Charts implemented using Lightweight Charts™